NCT02531516 2026-02-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT03520478 2021-03-02
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT00846976 2015-01-21
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00884273 2013-11-13
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Phase 3 Completed
NCT00831233 2013-11-11
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT00833248 2012-10-04
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00657904 2012-06-06
Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00233610 2011-01-27
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00672282 2009-05-27
SPCG6
AstraZeneca
Phase 3 Completed
NCT00841113 2009-02-11
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited
Phase 3 Completed